• Capacity for clinical trials across multiple centres
    • Development of biomarkers, both biochemical and morphological for susceptibility to disease and their modification in intervention studies eg biomarkers for negative symptoms of schizophrenia
    • Longitudinal studies to examine the nature, extent and timing of progressive brain changes in psychotic disorders including schizophrenia and mood disorder
    • Internationally unique database of 3,000+ participants with a range of neuropsychiatric conditions and at different stages of illness, treatment history, outcomes
  • Advanced imaging and electro-physiological investigations: e.g. structural and functional neuroimaging, magnetic resonance spectroscopy, diffusion tensor imaging, EEG and transcranial magnetic stimulation
  • Expertise in health economic evaluation of outcomes and cost of treatment